Insider Buying Opus Genetics, Inc. CEO Purchases 90,294 Shares of Stock
| IRD Stock | 1.11 0.06 5.71% |
About 72 percent of all Opus Genetics,'s shareholders are curious in acquiring. The analysis of overall sentiment of trading Opus Genetics, stock suggests that quite a large number of investors are confidant at this time. The current market sentiment, together with Opus Genetics,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Opus Genetics, stock news signals to limit their universe of possible portfolio assets.
Opus |
Opus Genetics, Inc. CEO George Magrath bought 90,294 shares of the companys stock in a transaction dated Friday, November 15th. The stock was purchased at an average price of 1.01 per share, with a total value of 91,196.94. Following the completion of the transaction, the chief executive officer now directly
Read at thelincolnianonline.com
 |
Opus Genetics, Fundamental Analysis
We analyze Opus Genetics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Opus Genetics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Opus Genetics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Opus Genetics, is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Opus Genetics, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Opus Genetics, stock to make a market-neutral strategy. Peer analysis of Opus Genetics, could also be used in its relative valuation, which is a method of valuing Opus Genetics, by comparing valuation metrics with similar companies.
Peers
Opus Genetics, Related Equities
Complementary Tools for Opus Stock analysis
When running Opus Genetics,'s price analysis, check to measure Opus Genetics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opus Genetics, is operating at the current time. Most of Opus Genetics,'s value examination focuses on studying past and present price action to predict the probability of Opus Genetics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opus Genetics,'s price. Additionally, you may evaluate how the addition of Opus Genetics, to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |